COMPANY INFO
Cardurion Pharmaceuticals is a biotechnology company founded in 2017 by physician-scientists Michael E. Mendelsohn, M.D. and Daniel Bloomfield, M.D. The company focuses on developing groundbreaking therapeutics for cardiovascular diseases, particularly targeting heart failure and arrhythmias through innovative clinical programs involving PDE9 and CaMKII inhibition. It is headquartered in Burlington, Massachusetts, with about 50-68 employees, and operates in the biotechnology industry. Their website is https://cardurion.com.
Cardurion Pharmaceuticals is a biotechnology company focused on developing groundbreaking therapeutics for cardiovascular diseases, such as heart failure and arrhythmias. Established in 2017, Cardurion Pharmaceuticals leverages innovative platforms including PDE9 and CaMKII inhibition to address urgent unmet needs in cardiology.
The Cardurion Pharmaceuticals executives team is comprised of industry leaders with deep expertise in biotechnology, finance, clinical development, and organizational management. The company’s leadership group is known for their extensive backgrounds in drug development, strategic operations, people management, and regulatory oversight, all of which contribute to the company’s momentum in advancing clinical programs and expanding a promising cardiovascular pipeline. This management team has successfully guided Cardurion through significant funding rounds, rapid organizational growth, and the complex landscape of biotech innovation.
Peter S. Lawrence, J.D., serves as President, CEO, and board member, shaping Cardurion Pharmaceuticals’ strategy for growth since March 2020. As the top leader among Cardurion Pharmaceuticals executives, Peter S. Lawrence brings over two decades of life sciences executive experience, known for success in company building, deal making, and operational oversight. He led the company through major funding rounds and clinical advances, drawing on a history that includes steering ArQule, Inc. through its $2.7 billion acquisition by Merck, and securing partnerships worth over $1 billion.
Lawrence holds a Bachelor’s degree in History and Russian Studies from Amherst College and a J.D. from Boston University School of Law. His career spans roles as founder and general partner at Pod Venture Partners, equity partner at Mintz Levin, and significant executive positions in biotech management.
Marcia D. Moore, M.P.H., is the Chief Operating Officer, responsible for Cardurion Pharmaceuticals’ operational strategy, clinical development, regulatory affairs, and organizational growth. Marcia D. Moore has over 30 years of experience, previously building scalable development organizations and driving IND filings as Senior VP of Strategic Operations at Arvinas. At Cardurion, she ensures successful execution of clinical and drug development plans, directly supporting the company's mission to advance its cardiovascular pipeline.
Moore holds a Master of Public Health from Yale University and a B.S. from Bates College. Her prior experience includes leadership roles at Alexion Pharmaceuticals and Bristol-Myers Squibb, with a strong focus on clinical research and development.
Elizabeth Radcliffe joined as Chief Financial Officer in January 2023, heading financial operations and strategic planning for Cardurion Pharmaceuticals. Elizabeth Radcliffe played a pivotal role in supporting clinical programs and driving the company’s financial strategy. Previously, she was CFO at Affinivax, successfully guiding its acquisition by GSK for up to $3.3 billion, and she has also held finance roles at Arrakis Therapeutics, Agios Pharmaceuticals, and Biogen.
Radcliffe earned a B.S. in Chemistry from Yale University, a Master's in Organic Chemistry from Harvard, and an MBA from MIT Sloan School of Management. Her expertise spans more than two decades in financial stewardship, business transformation, and strategic leadership within the biotech sector.
Karen Lewis joined Cardurion Pharmaceuticals as Chief People Officer in March 2025, where she is charged with developing the company’s people strategy, organizational design, and culture initiatives. Karen Lewis brings over 25 years of HR leadership in biotech and pharma, previously serving as Chief People Officer for Apellis Pharmaceuticals and holding senior HR positions at Biogen, Bristol-Myers Squibb, and Amazon.
Lewis holds a B.S. in Biology from Rider University. Her career in human resources is distinguished by a strong focus on talent acquisition and workforce engagement for rapidly growing biotech organizations.
Stephen Migausky, as Chief Legal Officer since January 2024, manages Cardurion Pharmaceuticals' legal, corporate governance, and compliance operations. Stephen Migausky has extensive experience advising biotech companies on strategic transactions and M&A, with previous tenures at Imara, ArQule, and Vertex Pharmaceuticals.
Migausky holds a B.A. in Economics and History from Colby College and a J.D. from Georgetown University Law Center. Prior to joining the industry, he was a corporate attorney at WilmerHale, specializing in corporate governance and transactional law.
Charlotte Newman, also known as Charlie, joined as Chief Business Officer in January 2025 and is tasked with leading Cardurion Pharmaceuticals’ business development, portfolio, and new product strategy. Charlotte Newman brings over 25 years of experience, previously heading business operations at Agios Pharmaceuticals and holding senior leadership roles at Biogen.
She holds a Bachelor’s in Animal Physiology with Biochemistry from the University of Leicester. Newman’s expertise centers on portfolio strategy, business growth, and clinical development operations in the biopharma industry.
Michael Crispin leads Cardurion Pharmaceuticals’ information technology strategy, enabling the digital backbone for innovation and growth. Michael Crispin is recognized for building high-performing IT teams and implementing advanced technologies to support biotech success, and he actively engages the community as a podcast co-host on IT in life sciences.
Crispin has over two decades of IT leadership in life sciences, with prior VP roles at Akebia Therapeutics and Keryx Biopharmaceuticals. He brings expertise in cloud computing, cybersecurity, enterprise architecture, and digital transformation.
Gary Budney directs quality and compliance at Cardurion Pharmaceuticals, ensuring strong GxP standards and consistently high product quality. Gary Budney oversees compliance for clinical and manufacturing operations, drawing on 30 years of experience at leading pharma and biotech companies, including Arvinas and Achillion Pharmaceuticals.
Budney holds a B.S. in Pharmacy from Duquesne University. His expertise covers GMP remediation, quality management systems, and supplier assurance, supporting Cardurion’s rigorous standards.
Michael Donaldson manages financial planning and operations for Cardurion Pharmaceuticals, supporting the company’s strategic and operational goals. Michael Donaldson has played pivotal roles in acquisitions and financial integrations throughout biotech finance, including SVP Finance at Goldfinch Bio and CFO at Summit Therapeutics.
Donaldson is a graduate of the University of Massachusetts Amherst and is a Certified Public Accountant. His background encompasses finance leadership positions at ARIAD Pharmaceuticals and Analog Devices.
Hillary McKellar (Brennan) leads clinical operations at Cardurion Pharmaceuticals, with responsibility for advancing clinical programs and regulatory submissions. Hillary McKellar (Brennan) is highly experienced in NDA and FDA readiness, particularly in rare disease and high unmet need spaces, having held leadership roles at Fulcrum Therapeutics, SAGE Therapeutics, and Sunovion Pharmaceuticals.
She earned a B.A. in Biology from Colby College. Her extensive career in clinical operations underpins Cardurion’s commitment to excellence in drug development.
The Cardurion Pharmaceuticals leadership team is composed of deeply experienced executives, each contributing unique expertise in areas like scientific innovation, financial stewardship, people management, and operational excellence. This dynamic mix supports effective decision-making, ensures comprehensive oversight, and enables Cardurion to deliver on its mission to develop novel cardiovascular therapeutics. Collectively, the management team and company founders combine visionary direction with operational discipline—key ingredients for Cardurion Pharmaceuticals’ ongoing growth and industry impact.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the Cardurion Pharmaceuticals leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.